(Dec 18, 2021 11:34 PM)Leigha Wrote: Heard today that the CDC might change the definition of “fully vaccinated” to two shots plus a booster.
The goal posts keep changing and the Pfizer CEO is discussing a fourth shot (second booster)
Hmm.
With J&J booted out of the whole mutable dynamics...
The tragedy of Johnson & Johnson’s Covid vaccine
https://www.statnews.com/2021/12/17/the-...d-vaccine/
INTRO:
Johnson & Johnson’s Covid vaccine was going to be a shot for the world. Now, under the weight of a mountain of bad PR, one wonders if the world will want it.
On Thursday, a panel advising the Centers for Disease Control and Prevention voted unanimously that the shots developed by Pfizer and Moderna
should be recommended over the J&J one. That won’t matter much to J&J as a business — in the third quarter the vaccine generated only $500 million of the company’s $23 billion in revenue.
But the recommendation is confusing news for the public, a slight to one of the world’s largest drug companies, and a disappointing setback for researchers, both inside and outside J&J, who hoped that the shot and the technology behind it would make a huge difference in the fight against a raging global pandemic. Decisions that J&J made seemingly in the service of public health, not commerce, may have hurt the vaccine’s chances, and in the end, the company was bested by one of the central facts of drug development: Biology is unfair, and, besides, you can’t be smart enough to beat bad luck.
The J&J Covid vaccine for a moment seemed like a crowning achievement for Paul Stoffels, J&J’s chief scientific officer and vice chairman, known for his career developing HIV and tuberculosis drugs as well as an Ebola vaccine. Whereas J&J’s reputation is anything but pristine — the company played a role in the opioid epidemic, and has faced lawsuits around antipsychotic drugs and even its famous talcum powder — Stoffels, a world-renowned scientist, stood out as bearish and warm. On the Covid vaccine, he was working with Harvard’s Dan Barouch, who was also working with J&J on an HIV vaccine.
Last January, Stoffels described to me the moment he knew that the vaccine might have legs. Johan Van Hoof, an executive in J&J’s vaccine business, sent him a photo of primate data on the vaccine candidate. The scientists were extremely happy but remained subdued — they joked it was because they are both Flemish. But Stoffels saved the photo on his phone.
Those kinds of moments took on a different color, though, as the one-dose form of the J&J vaccine turned out to have only 66% efficacy at preventing symptomatic SARS-CoV-2 infection compared with the vaccines developed by Moderna and the team of Pfizer and BioNTech, which showed efficacy in the range of 95%. Both of those competing vaccines use a technology called mRNA to prompt the body to make a protein from the virus that the immune system then learns to recognize; J&J’s vaccine instead uses a modified version of a virus, called adenovirus.
Any pharma marketer will tell you: Even a slight difference in efficacy numbers can sway patients and doctors... (
MORE - details)